| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 5.041 | 6.007 | 4.124 | 3.150 | 3.298 | 2.109 | 2.860 | 1.470 | 1.799 | 1.528 |
| Total Income - EUR | 5.041 | 6.007 | 4.124 | 3.150 | 3.298 | 2.109 | 2.860 | 1.470 | 1.799 | 1.528 |
| Total Expenses - EUR | 4.713 | 4.460 | 3.899 | 3.395 | 3.748 | 1.528 | 2.564 | 1.460 | 1.790 | 1.495 |
| Gross Profit/Loss - EUR | 328 | 1.546 | 225 | -245 | -450 | 581 | 296 | 10 | 10 | 33 |
| Net Profit/Loss - EUR | 177 | 1.366 | 102 | -339 | -549 | 539 | 296 | 10 | 4 | 28 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Biocuant S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 574 | 367 | 898 | 375 | 28 | 1.800 | 1.280 | 803 | 320 | 0 |
| Current Assets | 62 | 1.636 | 1.161 | 1.308 | 1.071 | 66 | 578 | 67 | 120 | 465 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 62 | 1.636 | 1.161 | 1.308 | 1.071 | 66 | 578 | 67 | 120 | 465 |
| Shareholders Funds | 622 | 1.982 | 2.050 | 1.673 | 1.092 | 1.610 | 1.871 | 58 | 62 | 90 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 26 | 33 | 21 | 22 | 20 | 269 | 0 | 811 | 390 | 387 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Biocuant S.r.l.